Chronic Lymphocytic Leukemia Through the Spectrum: Frontline Therapy, Sequencing With Subsequent Therapy, and Treatment of Double-Refractory Patients
American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)
DOI: 10.1200/edbk-26-517476 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Anna Maria Frustaci und 4 weiteren Autor:innen. Beteiligte Einrichtung: ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Department of Hematology, Milan, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit nennt 103 Literaturangaben.
Abstract (Originalsprache)
The rapid development of novel agents and combinations in chronic lymphocytic leukemia/small lymphocytic lymphoma has led to multiple options for frontline therapy and relapse, including continuous therapy and fixed duration regimens. The choice of therapy may be affected by the patient performance status, molecular abnormalities, potential side effects, logistics, patient expectations, and sequencing options in patients who will likely need more than one therapy in their lifetime. Current therapy options consist of several Bruton tyrosine kinase inhibitors (BTKis; covalent and noncovalent), one BCL-2 inhibitor (with others in development), and antibodies, with the possibility of single-agent therapy, doublets, or, less frequently, triplet therapy. In addition, treatment for double-refractory patients (refractory to both a BTKi and a BCL-2i) is available, but options are limited, so additional therapies for treatment in these high-risk patients are needed and in development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Department of Hematology, Milan, Italy.
- Department I of Internal Medicine and Medical Faculty, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Center of Excellence on "Cellular Stress Responses in Aging-Associated Diseases",…
- Chao Family Comprehensive Cancer Center, University of California, Irvine, CA.
Zitieren
APA
Frustaci, A. M., Tedeschi, A., Vom Stein, A. F., Hallek, M., & O'Brien, S. (2026). Chronic Lymphocytic Leukemia Through the Spectrum: Frontline Therapy, Sequencing With Subsequent Therapy, and Treatment of Double-Refractory Patients. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-517476
Vancouver
Frustaci AM, Tedeschi A, Vom Stein AF, Hallek M, O'Brien S. Chronic Lymphocytic Leukemia Through the Spectrum: Frontline Therapy, Sequencing With Subsequent Therapy, and Treatment of Double-Refractory Patients. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-517476
BibTeX
@article{Frustaci2026,
author = {Frustaci, Anna Maria and Tedeschi, Alessandra and Vom Stein, Alexander F and Hallek, Michael and O'Brien, Susan},
title = {Chronic Lymphocytic Leukemia Through the Spectrum: Frontline Therapy, Sequencing With Subsequent Therapy, and Treatment of Double-Refractory Patients},
journal = {American Society of Clinical Oncology Educational Book},
year = {2026},
volume = {46},
number = {3},
doi = {10.1200/edbk-26-517476}
}
EUVIMED